Cargando…

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients

BACKGROUND: Tumor mutational burden (TMB) has both prognostic value in resected non-small cell lung cancer (NSCLC) patients and predictive value for immunotherapy response. However, TMB evaluation by whole-exome sequencing (WES) is expensive and time-consuming, hampering its application in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Yanhua, Xu, Jiachen, Chu, Qian, Duan, Jianchun, Zhang, Jianjun, Bai, Hua, Yang, Zhenlin, Fang, Wenfeng, Cai, Liangliang, Wan, Rui, Fei, Kailun, He, Jie, Gao, Shugeng, Zhang, Li, Wang, Zhijie, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448445/ https://www.ncbi.nlm.nih.gov/pubmed/32843031 http://dx.doi.org/10.1186/s12916-020-01694-8

Ejemplares similares

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
por: Tian, Yanhua, et al.
Publicado: (2022)

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
por: Cai, Liangliang, et al.
Publicado: (2019)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
por: Sun, Yiting, et al.
Publicado: (2021)

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
por: Wang, Chao, et al.
Publicado: (2023)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer: A Phase 1 Trial
por: Wang, Zhijie, et al.
Publicado: (2020)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma
por: Xu, Jiachen, et al.
Publicado: (2023)

Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer
por: Du, Jun, et al.
Publicado: (2021)

Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2020)

Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer
por: Zuo, Ying, et al.
Publicado: (2022)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity
por: Liu, Lihui, et al.
Publicado: (2023)

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
por: Han, Jiefei, et al.
Publicado: (2021)

Multiple primary lung cancer: Updates of clinical management and genomic features
por: Tian, He, et al.
Publicado: (2023)

Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas
por: Sun, Sijin, et al.
Publicado: (2021)

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
por: Wang, Zhijie, et al.
Publicado: (2019)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq
por: Li, Qingqing, et al.
Publicado: (2022)

ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC
por: Yang, Zhenlin, et al.
Publicado: (2021)

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2020)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma
por: Liu, Tingting, et al.
Publicado: (2022)

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies
por: Fu, Shuai, et al.
Publicado: (2015)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

Pegylated recombinant human granulocyte colony‐stimulating factor regulates the immune status of patients with small cell lung cancer
por: Sun, Jing, et al.
Publicado: (2020)

Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis
por: Tian, He, et al.
Publicado: (2023)

A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma
por: Liu, Lei, et al.
Publicado: (2021)

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments
por: Duan, Jianchun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cptn9m12kpk12a4d7jbf2orin8